-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378

Benzinga·10/13/2026 12:58:54
Listen to the news
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.